Sabby Management’s Scinai Immunotherapeutics SCNI Stock Holding History

Sabby Management’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-17,828	Closed	-$49.6K	–	59
2024 Q2	$49.6K	Sell	17,828 -7,486	-30%	-$31.1K	0.03%	32
2024 Q1	$131K	Buy	25,314 +3,248	+15%	+$16.8K	0.08%	29
2023 Q4	$131K	Sell	22,066 -2,431	-10%	-$16.7K	0.13%	32
2023 Q3	$213K	Buy	24,497 +5,404	+28%	+$69.3K	0.16%	37
2023 Q2	$269K	Sell	19,093 -13,504	-41%	-$233K	0.22%	41
2023 Q1	$704K	Buy	32,597 +10,541	+48%	+$260K	0.61%	15
2022 Q4	$653K	Buy	+22,056	New	+$1.66M	0.57%	21
2017 Q4	–	Sell	-194	Closed	-$139K	–	183
2017 Q3	$139K	Buy	+194	New	+$159K	0.01%	134

Other funds holding SCNI

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sabby Management's SCNI Position: Q3 2024 in Review

Sabby Management sold out of Scinai Immunotherapeutics (SCNI) in Q3 2024, closing a stake of 17,828 shares — an estimated $49.6K sold.

Sabby Management first reported a position in SCNI in Q3 2017 and held it in 8 quarters. The position peaked at $704K in Q1 2023. 5 funds tracked by Wall St. Rank hold SCNI as of Q3 2024.

Sabby Management reported no remaining Scinai Immunotherapeutics position as of Q3 2024 after selling out during the quarter.
Sabby Management sold 17,828 Scinai Immunotherapeutics shares in Q3 2024, an estimated $49.6K.
Sabby Management first reported a position in Scinai Immunotherapeutics in Q3 2017 and held it in 8 quarters.
Sabby Management's Scinai Immunotherapeutics position peaked at $704K in Q1 2023.
5 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q3 2024.

Based on Sabby Management's 13F filing for Q3 2024, filed 14 Nov 2024.